Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ExoElite (also known as ExoElite 70) is an exosome-based biologic product developed by Cellgenic, a company associated with the Global Stem Cells Group. It is a high-potency formulation containing 70 billion pure exosomes per vial, which are cell-derived nanoparticles that facilitate cell-to-cell communication. The product is designed to support tissue repair and regeneration through exosome-mediated paracrine signaling. It is marketed for various regenerative medicine applications, including skin rejuvenation, wound healing, orthopedic therapies, and general tissue repair. ExoElite is positioned as a commercial regenerative product rather than a candidate in a traditional clinical development pipeline.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ExoElite.